Alternative splicing variants of human arsenic (+3 oxidation state) methyltransferase

Biochemical and Biophysical Research Communications

Volumn 415, Issue 1, 2011, Pages 48-53

  Sumi, Daigo ^a   Fukushima, Kayo ^a   Miyataka, Hideki ^a   Himeno, Seiichiro ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Alternative splicing; Arsenic (+3 oxidation state) methyltransferase; Methyltransferase activity

Indexed keywords

ARSENIC ACID DERIVATIVE; ARSENIC METHYLTRANSFERASE; CYSTEINE; METHYLTRANSFERASE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; CODON; CONTROLLED STUDY; ENZYME ACTIVITY; ESCHERICHIA COLI; EXON; GENE DELETION; GENE IDENTIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; MASS SPECTROMETRY; METHYLATION; OXIDATION; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; ARSENIC; HEP G2 CELLS; HUMANS; ISOENZYMES; METHYLATION; METHYLTRANSFERASES;

ESCHERICHIA COLI;

EID: 80755140610     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.008     Document Type: Article

References (36)

1. Nordstrom D.K. Public health. Worldwide occurrences of arsenic in ground water. Science 2002, 296:2143-2145.
2. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339:1341-1348.
3. Aposhian H.V., Aposhian M.M. Arsenic toxicology: five questions. Chem. Res. Toxicol. 2006, 19:1-15.
4. Hayakawa T., Kobayashi Y., Cui X., Hirano S. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol. 2005, 79:183-191.
5. Kumagai Y., Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:243-262.
6. Lin S., Shi Q., Nix F.B., Styblo M., Beck M.A., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., Thomas D.J. A novel S-adenosyl-l-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 2002, 277:10795-10803.
7. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 2000, 74:289-299.
8. Hirano S., Kobayashi Y. Cytotoxic effects of S-(dimethylarsino)-glutathione: a putative intermediate metabolite of inorganic arsenicals. Toxicology 2006, 227:45-52.
9. Sakurai T., Kojima C., Kobayashi Y., Hirano S., Sakurai M.H., Waalkes M.P., Himeno S. Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215). Br. J. Pharmacol. 2006, 149:888-897.
10. Yokohira M., Arnold L.L., Pennington K.L., Suzuki S., Kakiuchi-Kiyota S., Herbin-Davis K., Thomas D.J., Cohen S.M. Severe systemic toxicity and urinary bladder cytotoxicity and regenerative hyperplasia induced by arsenite in arsenic (+3 oxidation state) methyltransferase knockout mice. A preliminary report. Toxicol. Appl. Pharmacol. 2010, 246:1-7.
11. Yokohira M., Arnold L.L., Pennington K.L., Suzuki S., Kakiuchi-Kiyota S., Herbin-Davis K., Thomas D.J., Cohen S.M. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3 oxidation state) methyltransferase knockout mice. Toxicol. Sci. 2011, 121:257-266.
12. Drobna Z., Naranmandura H., Kubachka K.M., Edwards B.C., Herbin-Davis K., Styblo M., Le X.C., Creed J.T., Maeda N., Hughes M.F., Thomas D.J. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem. Res. Toxicol. 2009, 22:1713-1720.
13. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72:291-336.
14. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6:386-398.
15. Kashima T., Rao N., Manley J.L. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 2007, 104:3426-3431.
16. Nishida A., Kataoka N., Takeshima Y., Yagi M., Awano H., Ota M., Itoh K., Hagiwara M., Matsuo M. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat. Commun. 2011, 2:308.
17. D. Sumi, T. Sasaki, H. Miyataka, S. Himeno, Rat H9c2 cardiac myocytes are sensitive to arsenite due to a modest activation of transcription factor Nrf2, Arch. Toxicol., in press.
18. Watanabe T., Ohta Y., Mizumura A., Kobayashi Y., Hirano S. Analysis of arsenic metabolites in HepG2 and AS3MT-transfected cells. Arch. Toxicol. 2011, 577-588.
19. Hamahata A., Takata Y., Gomi T., Fujioka M. Probing the S-adenosylmethionine-binding site of rat guanidinoacetate methyltransferase. Effect of site-directed mutagenesis of residues that are conserved across mammalian non-nucleic acid methyltransferases. Biochem. J. 1996, 317(Pt 1):141-145.
20. Gomi T., Tanihara K., Date T., Fujioka M. Rat guanidinoacetate methyltransferase: mutation of amino acids within a common sequence motif of mammalian methyltransferase does not affect catalytic activity but alters proteolytic susceptibility. Int. J. Biochem. 1992, 24:1639-1649.
21. Song X., Geng Z., Li X., Zhao Q., Hu X., Zhang X., Wang Z. Functional and structural evaluation of cysteine residues in the human arsenic (+3 oxidation state) methyltransferase (hAS3MT). Biochimie 2011, 93:369-375.
22. Song X., Geng Z., Zhu J., Li C., Hu X., Bian N., Zhang X., Wang Z. Structure-function roles of four cysteine residues in the human arsenic (+3 oxidation state) methyltransferase (hAS3MT) by site-directed mutagenesis. Chem. Biol. Interact. 2009, 179:321-328.
23. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40:1413-1415.
24. Wang E.T., Sandberg R., Luo S., Khrebtukova I., Zhang L., Mayr C., Kingsmore S.F., Schroth G.P., Burge C.B. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
25. Anthony K., Gallo J.M. Aberrant RNA processing events in neurological disorders. Brain Res. 2010, 1338:67-77.
26. Pistoni M., Ghigna C., Gabellini D. Alternative splicing and muscular dystrophy. RNA Biol. 2010, 7:441-452.
27. Venables J.P., Klinck R., Koh C., Gervais-Bird J., Bramard A., Inkel L., Durand M., Couture S., Froehlich U., Lapointe E., Lucier J.F., Thibault P., Rancourt C., Tremblay K., Prinos P., Chabot B., Elela S.A. Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 2009, 16:670-676.
28. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010, 24:2343-2364.
29. De Chaudhuri S., Ghosh P., Sarma N., Majumdar P., Sau T.J., Basu S., Roychoudhury S., Ray K., Giri A.K. Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ. Health Perspect. 2008, 116:501-505.
30. Engstrom K., Vahter M., Mlakar S.J., Concha G., Nermell B., Raqib R., Cardozo A., Broberg K. Polymorphisms in arsenic (+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect. 2011, 119:182-188.
31. Fujihara J., Soejima M., Koda Y., Kunito T., Takeshita H. Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Mutat. Res. 2008, 654:158-161.
32. Meza M.M., Yu L., Rodriguez Y.Y., Guild M., Thompson D., Gandolfi A.J., Klimecki W.T. Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. Environ. Health Perspect. 2005, 113:775-781.
33. Drobna Z., Waters S.B., Walton F.S., LeCluyse E.L., Thomas D.J., Styblo M. Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Toxicol. Appl. Pharmacol. 2004, 201:166-177.
34. Hernandez A., Xamena N., Surralles J., Sekaran C., Tokunaga H., Quinteros D., Creus A., Marcos R. Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat. Res. 2008, 637:80-92.
35. Agusa T., Iwata H., Fujihara J., Kunito T., Takeshita H., Minh T.B., Trang P.T., Viet P.H., Tanabe S. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol. 2009, 236:131-141.
36. Valenzuela O.L., Borja-Aburto V.H., Garcia-Vargas G.G., Cruz-Gonzalez M.B., Garcia-Montalvo E.A., Calderon-Aranda E.S., Del Razo L.M. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ. Health Perspect. 2005, 113:250-254.